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Brooke-Spiegler syndrome (BSS; OMIM 605041) has 
been described as an autosomal dominant disease charac-
terized by the development of a wide variety and number 
of skin appendage tumours not commonly found in the 
general population, such as cylindromas, trichoepithelio-
mas and spiradenomas (1, 2). The tumours grow slowly 
in size and number throughout life and may give rise to 
a large confluent mass on the head, historically referred 
to as turban tumours (1, 2).
The gene responsible for BSS, the cylindromatosis 
gene (CYLD), is localized on 16q12-q13 (2). So far more 
than 79 mutations have been identified, with clustering 
at the 3’ end of the CYLD gene, which encodes for the 
catalytic (exons 8–20) (3, 4). These mutations have been 
identified in patients with phenotypic features of either 
BSS, familial cylindromatosis (FC; OMIM 132700) 
or multiple familial trichoepithelioma type 1 (MFT1; 
OMIM 601606), suggesting that these 3 syndromes are 
phenotypic variations of the same genetic disease (5, 6).
A Hungarian pedigree from Bukovina (Romania) af-
fected by BSS and an English pedigree from northern 
England were included in this study.
MATERIALS AND METHODS
After ethical approval from Hungarian ethics committee (ETT 
TUKEB and REC REF: 06/059), blood samples were taken 
from the affected and unaffected family members, as well as 
from unrelated controls for genetic analysis. Genomic DNA has 
been isolated by a BioRobot EZ1 DSP Workstation (Qiagen; 
Hilden, Germany). After the amplification of the coding regions 
of the CYLD gene and the flanking introns (primers were used 
as displayed on the UCSC Genome Browser www.genome.ucsc.
edu), DNA sequencing was performed.
For the haplotype analysis, common polymorphisms 
(rs117347778, rs118122197, rs28705891, rs28654666, 
rs112993837, rs60077744, rs2160683, rs115042932, 
rs117998712, rs116979331, rs74822565, rs117713908, 
rs3743781, rs117537927, rs116971974, rs114552144) located 
in the 3’ and 5’ prime region of the identified mutation were 
genotyped using direct sequencing of the flanking coding and 
non-coding regions of the CYLD gene. Assay conditions and flan-
king sequences for the polymorphisms are available on request.
RESULTS
We identified 21 affected family members in the 7-ge-
neration Bukovinian family. The affected individuals 
had extensive skin appendage tumours, with some 
demonstrating “turban tumours” from numerous cylin-
dromas as well as trichoepitheliomas on the face (Fig. 
1). The tumours appeared in early life as small nodules 
and progressively enlarged, and also developed on the 
back and on the extremities of the patients. 
The Anglo-Saxon BSS pedigree from the north of 
England contained 8 affected family members span-
ning 5 generations. The affected individuals had a 
comparatively milder phenotype, with cylindromas and 
spiradenomas on the scalp and trichoepitheliomas on 
the face (Fig. 2). 
Direct sequencing of the coding regions and the 
flanking introns of the CYLD gene revealed a hetero-
zygous nonsense mutation (c.2806C>T, p.Arg936X) 
in exon 20 in affected family members of the Hunga-
rian and Anglo-Saxon pedigrees (Fig. S1a; available 
from: http://www.medicaljournals.se/acta/content/
?doi=10.2340/00015555-1590). Clinically unaffec-
ted family members carried the wild-type sequence 
(Fig. S1b). Delineation of the surrounding common 
polymorphisms indicated different haplotypes in the 
investigated BSS pedigrees (Fig. S1c). 
DISCUSSION
The identified mutation (c.2806C>T, p.Arg936X) was 
first reported by Bignell et al. (2) and later by Bowen 
et al. (7) in a European and a Canadian BSS pedigree. 
Haplotype analysis of the Hungarian and the Anglo-
Saxon BSS pedigrees demonstrated that the same muta-
tion carried by the 2 geographically distant pedigrees 
was the result of 2 independent mutational events. 
Previous haplotype analyses have demonstrated ex-
amples when identical CYLD mutations in independent 
BSS families were associated with the same haplotypes 
(c.2469+1G>A) and also when identical CYLD mu-
tations in independent BSS families were associated 
with different haplotypes and different founder events 
(c.2272C>T p.Arg758X) (2). It is notable that the pre-
viously reported mutation (c.2272C>T p.Arg758X) in 
independent BSS pedigrees with different haplotypes 
is also a nonsense mutation affecting an arginine (2), 
as is the case for the mutation reported in the investi-
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gated Hungarian and Anglo-Saxon BSS pedigrees 
(c.2806C>T, p.Arg936X). We hypothesize that these 
positions may be mutational hotspots on the CYLD 
gene. Notably, these hotspots occur in sequence of 
the gene that encodes the catalytic residues of CYLD, 
suggesting that a dominant negative effect may be 
important in manifesting a phenotype (8, 9). 
There are previous studies in the literature that have 
also reported huge phenotypic heterogeneity even 
within the same BSS pedigrees (10–12). This raises 
the putative role of either environmental factors or 
modifying genes, which influence the clinical phe-
notype of the BSS patients (2, 11). A recent report by 
Rajan et al. (12) provided the first clinical evidence that 
hormonally sensitive hair follicles 
may be predisposed to tumour 
formation, potentially implicating 
the role of hormonal factors in 
tumour induction in BSS patients. 
It is anticipated that further gene-
tic research may highlight genetic 
or epigenetic variation that could 
predict the development of a severe 
phenotype. The identification of 
such changes are important in the 
prognostic counselling of CYLD 
mutation carriers and could influ-
ence the early treatment of these 
patients with approaches such as 
kinase inhibition with TRK inhi-
bitors to prevent the development 
of the disfiguring “turban tumour” 
phenotype (6).
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Fig. 1. The Hungarian BSS pedigree of 
Bukovinian (Romanian) origin. The clinical 
pictures of the severe hairy scalp symptoms of 
the affected individuals are represented from the 
(a) 2nd, (b) 3rd (c, d) 4th and 5th (e) generations. (f) 
The pedigree contains 21 affected family members 
spanning 7 generations.
Fig. 2. The investigated Anglo-
Saxon pedigree from the north 
of England. Clinical pictures of 
the affected individuals from the 
4th generation show tumours (a) 
above the ear, (b) on the forehead, 
and (c) around the nose. (d) The 
pedigree contains 8 affected 
family members spanning 5 
generations.
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